title: Treatment of advanced soft tissue sarcomas with ifosfamide and doxorubicin combination chemotherapy.
abstract: Our objective was to assess the efficacy of a standard dose ifosfamide and doxorubicin containing regimen in the treatment of advanced soft tissue sarcomas. Forty consecutive patients with a median age of 35.5 years were treated. Ifosfamide was administered at a dose of 2.5 g/m(2)/day as 72-hour continuous infusion with mesna at the same dosage and schedule. Doxorubicin was given at the dose of 60 mg/m(2)/day as 2-hour infusion on day 1. Six patients had a complete response (15%), and 9 (22.5%) had a partial response, fourteen patients (35%) stable disease, and 11 (27.5%) did not respond to chemotherapy. The median duration of response was 13 and 5 months for the complete and partial responders, respectively. The median survival was 37 months. Febrile neutropenia was encountered in 9 cases (22.5%). The present ifosfamide and doxorubicin combination is a moderately effective and well-tolerable regimen in the treatment of advanced soft tissue sarcomas.
authors.affiliation: Department of Medical Oncology, Institute of Oncology, Hacettepe University, Ankara, Turkey.
authors.forename: I
authors.initials: I
authors.lastname: Barişta
authors.forename: G
authors.initials: G
authors.lastname: Tekuzman
authors.forename: S
authors.initials: S
authors.lastname: Yalçin
authors.forename: I
authors.initials: I
authors.lastname: Güllü
authors.forename: N
authors.initials: N
authors.lastname: Güler
authors.forename: Y
authors.initials: Y
authors.lastname: Ozişik
authors.forename: A
authors.initials: A
authors.lastname: Kars
authors.forename: I
authors.initials: I
authors.lastname: Celik
authors.forename: A
authors.initials: A
authors.lastname: Türker
authors.forename: K
authors.initials: K
authors.lastname: Altundağ
authors.forename: N
authors.initials: N
authors.lastname: Zengin
authors.forename: A
authors.initials: A
authors.lastname: Uner
authors.forename: E
authors.initials: E
authors.lastname: Baltali
authors.forename: D
authors.initials: D
authors.lastname: Firat
mesh_terms: D000293:Adolescent; D000328:Adult; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage* / Q000009:adverse effects; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage* / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D004317:Doxorubicin / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D005334:Fever / Q000139:chemically induced; D005500:Follow-Up Studies; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage* / Q000009:adverse effects; D007262:Infusions, Intravenous; D016015:Logistic Models; D008297:Male; D015080:Mesna / Q000627:therapeutic use; D008875:Middle Aged; D009503:Neutropenia / Q000139:chemically induced; D020011:Protective Agents / Q000627:therapeutic use; D012074:Remission Induction; D012509:Sarcoma / Q000188:drug therapy*; D015996:Survival Rate
chemical_list: D000903:Antibiotics, Antineoplastic; D018906:Antineoplastic Agents, Alkylating; D020011:Protective Agents; D004317:Doxorubicin; D015080:Mesna; D007069:Ifosfamide